Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement - Wikidata - wikimedia - TriplyDB

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

http://www.wikidata.org/entity/Q33384243

about

Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin or unfractionated heparin.Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty.Induction of anti-PF4/heparin antibodies after arthroplasty for rheumatic diseases.

P2860

Q33399791-0FD49990-D0EC-4708-9B8D-0C45401AE5F4 Q33434832-4293962B-5A22-4447-97F3-015DBACF102F Q54942463-25F33EB8-B439-4FE2-B10C-853E02D47CA2

P2860

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

http://www.wikidata.org/entity/Q33384243

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

@ast

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

@en

type

label

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

@ast

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

@en

prefLabel

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

@ast

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

@en

P1433

Q33384243-BCDE90E9-1267-476C-B4CF-121A66B21F45

P1476

Q33384243-EC0BB9E6-E022-46DB-9AD4-74CA57A98C56

P2093

Q33384243-1D8EFFD2-08B9-481F-BF50-FC1A1EEDE3AE

Q33384243-32D1A080-5AC6-4530-AACE-F6506F889CEF

Q33384243-4A9DE884-E720-4A86-A17C-C7A7308FC486

Q33384243-7870B48B-7348-4C73-80E1-C77FDFC75317

Q33384243-9D7CA403-95A0-4958-9196-E87B980F87F5

Q33384243-C5FAE027-D9BA-4720-9DEB-06822E24658A

Q33384243-CB4FCDB1-488E-43F6-9151-AEBFCE0AF835

Q33384243-D6766D3A-1514-4A19-B9CF-27558EB8A3D2

Q33384243-E4572739-BF39-4259-BD62-72AED5941736

P2860

Q33384243-0AB384EE-6DD7-4317-BD6F-47141BDAEF8A

Q33384243-1EEE127D-738F-4947-84EB-A5A8FD29F5CB

Q33384243-2255091F-6957-4E3B-9836-1871FF1E0222

Q33384243-26E11D61-5CD6-4480-9925-5ECA478D2431

Q33384243-2FC338A0-46F7-4BA4-96E3-1DFCE39328FC

Q33384243-308BA1D9-811D-4B7F-8154-66F61816803F

Q33384243-344C893E-8185-4842-A0D9-9E517A19473B

Q33384243-490417D3-A08E-41F8-9F52-2339F59C5AD7

Q33384243-5C873ED4-7859-4A18-AF05-712B9B25AB4C

Q33384243-5CEAAA8F-41C2-4583-8067-654318646CC5

P2888

Q33384243-9E97150D-0279-45CC-9EA7-C0A91B0F2874

P304

Q33384243-08F1BDCF-1749-42C6-9008-7F7C9EC9E206

P31

Q33384243-6C068F91-44BC-4223-8A31-DA69E0BBCDA5

P356

Q33384243-72D10342-D461-4457-92A0-7EAE1AA14ABC

P478

Q33384243-C0B8DBE1-1C70-4ADE-8AA9-5145A0D8346C

P577

Q33384243-E31316DD-94E9-4155-93BF-E41DF0A47C11

P5875

Q33384243-9F8219C8-9A54-4BBF-9823-8883A24C20C2

P6179

Q33384243-3393E3FE-898B-41D4-8430-5540ADC920DD

P698

Q33384243-75914B6D-68D4-4ADF-B5F7-A89D087619CD

P932

Q33384243-47D065CF-5141-441E-8E53-06B58310D375

P356

1471-2474-10-42

P1433

BMC Musculoskeletal Disorders

P1476

Clinical relevance of heparin-PF4 complex antibody in DVT after total joint replacement

@en

P2093

Gou Takayama

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Shindo

http://www.w3.org/2001/XMLSchema#string

Kazushige Maeda

http://www.w3.org/2001/XMLSchema#string

Kenji Taguchi

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Migita

http://www.w3.org/2001/XMLSchema#string

Satoru Motokawa

http://www.w3.org/2001/XMLSchema#string

Takafumi Torigoshi

http://www.w3.org/2001/XMLSchema#string

Takeshi Hiura

http://www.w3.org/2001/XMLSchema#string

Yumi Maeda

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Heparin-induced thrombocytopenia: a clinicopathologic syndrome.

Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.

Temporal aspects of heparin-induced thrombocytopenia.

Heparin-induced thrombocytopenia: an overview.

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

Heparin-induced thrombocytopenia: clinical manifestations and management strategies.

Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.

Clinical practice. Heparin-induced thrombocytopenia.

Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes.

P2888

1471-2474-10-42

P304

42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2474-10-42

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24364929

http://www.w3.org/2001/XMLSchema#string

P6179

1004088652

http://www.w3.org/2001/XMLSchema#string

P698

19397833

http://www.w3.org/2001/XMLSchema#string

P932

2685118

http://www.w3.org/2001/XMLSchema#string